Disclosures for "Cerebral Small Vessel Disease Subtypes and Blood Pressure Control after Intracerebral Hemorrhage")
-
Dr. Mallick has nothing to disclose.
-
Dr. Das has nothing to disclose.
-
Ms. Keins has nothing to disclose.
-
Jessica Abramson has nothing to disclose.
-
Juan Pablo Castello, MD has nothing to disclose.
-
Marco Pasi has nothing to disclose.
-
Dr. Popescu has nothing to disclose.
-
Leidys Gutierrez-Martinez has nothing to disclose.
-
Dr. Mayerhofer has nothing to disclose.
-
Christina Kourkoulis has nothing to disclose.
-
Axana Rodriguez-Torres has nothing to disclose.
-
Andrew d. Warren has nothing to disclose.
-
Mrs. Gokcal has nothing to disclose.
-
Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals.
-
Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Washington University/IQVIA. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
-
The institution of Dr. Anderson has received research support from Bayer AG. An immediate family member of Dr. Anderson has received publishing royalties from a publication relating to health care.
-
Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rosand has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Boehringer Ingelheim. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from OneMind. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Board Member with Columbia University that is relevant to AAN interests or activities.
-
The institution of Dr. Gurol has received research support from NIH/NINDS. The institution of Dr. Gurol has received research support from Boston Scientific Corporation. The institution of Dr. Gurol has received research support from AVID (a wholly owned subsidiary of Eli Lilly). The institution of Dr. Gurol has received research support from Pfizer.
-
Dr. Biffi has nothing to disclose.